Jong-Rung Tsai

Dr. Jong-Rung Tsai

respiratory and critical care, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JTJong-Rung Tsai
Jong-Rung Tsai
PLPo-Len Liu
Po-Len Liu
Yung-Hsiang ChenYung-Hsiang Chen
Yung-Hsiang Chen
SCShah-Hwa Chou
Shah-Hwa Chou
YCYu-Jen Cheng
Yu-Jen Cheng
ICInn-Wen Chong
Inn-Wen Chong
Adipose tissue is now considered as an endocrine organ involved in metabolic and inflammatory reactions. Adiponectin, a 244–amino acid peptide hormone, is associated with insulin resistance and carcinogenesis. Curcumin (diferuloylmethane) is the principal curcuminoid of the popular Indian spice, turmeric. Curcumin possesses antitumor effects, including the inhibition of neovascularization and regulation of cell cycle and apoptosis. However, the effects of adiponectin and curcumin on non-small cell lung cancer (NSCLC) remain unclear. In this study, we evaluated the expression of adiponectin in paired tumors and normal lung tissues from 77 patients with NSCLC using real-time polymerase chain reaction, western blotting, and immunohistochemistry. Kaplan–Meier survival analysis showed that patients with low adiponectin expression ratio (1) (p = 0.015). Curcumin inhibited the migratory and invasive ability of A549 cells via the inhibition of adiponectin expression by blocking the adiponectin receptor 1. Curcumin treatment also inhibited the in vivo tumor growth of A549 cells and adiponectin expression. These results suggest that adiponectin can be a prognostic indicator of NSCLC. The effect of curcumin in decreasing the migratory and invasive ability of A549 cells by inhibiting adiponectin expression is probably mediated through NF-κB/MMP pathways. Curcumin could be an important potential adjuvant therapeutic agent for lung cancer in the future.

1 May 2007 in Lung Cancer
Verified
Journal Article
Closed access
JTJong-Rung Tsai
Jong-Rung Tsai
ICInn-Wen Chong
Inn-Wen Chong
YCYan-Hua Chen
Yan-Hua Chen
MYMing-Je Yang
Ming-Je Yang
CSChau-Chyun Sheu
Chau-Chyun Sheu
SLShiu-Ru Lin
Shiu-Ru Lin

14 August 2013 in Archives of Pharmacal Research
Verified
Journal Article
Closed access
PDF file
JTJong-Rung Tsai
Jong-Rung Tsai
ICInn-Wen Chong
Inn-Wen Chong
Yung-Hsiang ChenYung-Hsiang Chen
Yung-Hsiang Chen
JHJhi-Jhu Hwang
Jhi-Jhu Hwang
WYWei-Hsian Yin
Wei-Hsian Yin
PLPo-Len Liu
Po-Len Liu

27 February 2020 in Annals of Intensive Care
Verified
Journal Article
Open access
PDF file
Ming-Ju TsaiMing-Ju Tsai
Ming-Ju Tsai
KYKuang-Yao Yang
Kuang-Yao Yang
MCMing-Cheng Chan
Ming-Cheng Chan
KKKuo-Chin Kao
Kuo-Chin Kao
HWHao-Chien Wang
Hao-Chien Wang
CSChau-Chyun Sheu
Chau-Chyun Sheu
Corticosteroid treatment has been widely used in the treatment of septic shock, influenza, and ARDS, although some previous studies discourage its use in severe influenza patients. This multicenter retrospective cohort study conducted in the intensive care units (ICUs) of eight medical centers across Taiwan aims to determine the real-world status of corticosteroid treatment in patients with influenza-associated acute respiratory distress syndrome (ARDS) and its impact on clinical outcomes. Between October 2015 and March 2016, consecutive ICU patients with virology-proven influenza infections who fulfilled ARDS and received invasive mechanical ventilation were enrolled. The impact of early corticosteroid treatment (≥ 200 mg hydrocortisone equivalent dose within 3 days after ICU admission, determined by a sensitivity analysis) on hospital mortality (the primary outcome) was assessed by multivariable logistic regression analysis, and further confirmed in a propensity score-matched cohort. Among the 241 patients with influenza-associated ARDS, 85 (35.3%) patients receiving early corticosteroid treatment had similar baseline characteristics, but a significantly higher hospital mortality rate than those without early corticosteroid treatment [43.5% (37/85) vs. 19.2% (30/156), p < 0.001]. Early corticosteroid treatment was independently associated with increased hospital mortality in overall patients [adjusted odds ratio (95% CI) = 5.02 (2.39–10.54), p < 0.001] and in all subgroups. Earlier treatment and higher dosing were associated with higher hospital mortality. Early corticosteroid treatment was associated with a significantly increased odds of subsequent bacteremia [adjusted odds ratio (95% CI) = 2.37 (1.01–5.56)]. The analyses using a propensity score-matched cohort showed consistent results. Early corticosteroid treatment was associated with a significantly increased hospital mortality in adult patients with influenza-associated ARDS. Earlier treatment and higher dosing were associated with higher hospital mortality. Clinicians should be cautious while using corticosteroid treatment in this patient group.

11 March 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JTJong-Rung Tsai
Jong-Rung Tsai
PLPo-Len Liu
Po-Len Liu
Yung-Hsiang ChenYung-Hsiang Chen
Yung-Hsiang Chen
SCShah-Hwa Chou
Shah-Hwa Chou
MYMing-Chan Yang
Ming-Chan Yang
ICInn-Wen Chong
Inn-Wen Chong
Heat-shock proteins (HSPs) are molecular chaperones that protect proteins from damage. HSP27 expression is associated with cancer transformation and invasion. Ginkgo biloba extract (EGb761), the most widely sold herbal supplement, has antiangiogenic effects and induces tumor apoptosis. Data regarding the effect of EGb761 on HSP expression is limited, particularly in cancer. HSP27 expression in paired tumors and normal lung tissues of 64 patients with non-small cell lung cancer (NSCLC) were detected by real-time PCR, western blotting, and immunohistochemistry. NSCLC cell lines (A549/H441) were used to examine the migratory abilities in vitro . NSCLC tissue showed higher HSP27 expression than normal lung tissue. Kaplan–Meier survival analysis showed that NSCLC patients with low HSP27 expression ratio (1) (p = 0.04). EGb761 inhibited HSP27 expression and migratory ability of A549/H441 cells, which is the same as HSP27-siRNA transfection effect. Moreover, EGb761 treatment activated the AKT and p38 pathways and did not affect the expression of PI3K, ERK, and JNK pathways. HSP27 is a poor prognostic indicator of NSCLC. EGb761 can decrease the migration ability of A549/H441 by inhibiting HSP27 expression most likely through AKT and p38 MAPK pathways activation.

18 February 2010 in The Kaohsiung Journal of Medical Sciences
Verified
Journal Article
Open access
CWCheng‐Yuan Wang
Cheng‐Yuan Wang
KLKai‐Huang Lin
Kai‐Huang Lin
CYChih‐Jen Yang
Chih‐Jen Yang
JTJong-Rung Tsai
Jong-Rung Tsai
JHJen‐Yu Hung
Jen‐Yu Hung
MHMing‐Shyan Huang
Ming‐Shyan Huang
Toona sinensis extracts have been shown to exhibit anti‐cancer effects in human ovarian cancer cell lines, human promyelocytic leukemia cells and human lung adenocarcinoma. Its safety has also been confirmed in animal studies. However, its anti‐cancer properties in human lung large cell carcinoma have not been studied. Here, we used a powder obtained by freeze‐drying the super‐natant of centrifuged crude extract from Toona sinensis leaves (TSL‐1) to treat the human lung carcinoma cell line H661. Cell viability was evaluated by the 3‐(4‐,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyl tetrazolium bromide assay. Flow cytometry analysis revealed that TSL‐1 blocked H661 cell cycle progression. Western blot analysis showed decreased expression of cell cycle proteins that promote cell cycle progression, including cyclin‐dependent kinase 4 and cyclin D1, and increased the expression of proteins that inhibit cell cycle progression, including p27. Furthermore, flow cytometry analysis showed that TSL‐1 induced H661 cell apoptosis. Western blot analysis showed that TSL‐1 reduced the expression of the anti‐apoptotic protein B‐cell lymphoma 2, and degraded the DNA repair protein, poly(ADP‐ribose) polymerase. TSL‐1 shows potential as a novel therapeutic agent or for use as an adjuvant for treating human lung large cell carcinoma.